ArticleMolecular biology reports2026

Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways.

Heba M Abd El Kareem et al.PubMed ↗Publisher ↗

No numbers read from the abstract.